Explorer les evidences

Palier Gold : evidences validées mécaniquement, avec leur source primaire.

148 evidences · page 3 / 6

9,7 %Among 982 participants, 9.7% believed HPV causes cancer.

Nigeriainfection à HPVpublié 2025Sexual healthPubMeddocument de 9 observations

8 %HPV prevalence was 8% among the general population.

Nigeriainfection à HPVobservé 2021publié 2023BMC public healthPubMeddocument de 12 observations

38,7 %The proportion of mothers who underwent HPV-related screening increased from 38.7% pre-sensitization to 52.4% 12-month post-sensitization, with statistical significance (p < 0.0001).

Nigeriainfection à HPVobservé 12-month post-sensitizationpublié 2026Journal of the International AIDS SocietyPubMeddocument de 5 observations

25,8 %In the study, 25.8% of the 801 students in four secondary schools in Benin City, Nigeria, were willing to receive the HPV vaccine when available.

Nigeriainfection à HPVpublié 2026International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument de 10 observations

35 %35% of the participants correctly stated the best time for the HPV vaccine.

Nigeriainfection à HPVpublié 2024BMC public healthPubMeddocument de 12 observations

16 %HPV prevalence was 16% among women living with HIV (WLHIV).

Nigeriainfection à HPVobservé 2021publié 2023BMC public healthPubMeddocument de 12 observations

48,1 %48.1% of the participants noted that HPV can cause cervical cancer.

Nigeriacancer du col de l'utérus · infection à HPVpublié 2024BMC public healthPubMeddocument de 12 observations

17,3 %In the study, 51 out of 295 individuals (17.3%) were positive for HPV DNA using consensus primers that target the E6/E7 genes.

Nigeriainfection à HPVpublié 2019PloS onePubMeddocument de 7 observations

88 %Among 213 women aged 16 to 63 years recruited in Lagos, Nigeria, 187 out of 213 participants had concordant HPV test results, representing 88% of total participants.

Nigeriainfection à HPVobservé 2020publié 2022BMC public healthPubMeddocument de 5 observations

0,5 %Only 1 person (0.5%) among 215 female secondary school students in Benin City, Nigeria had received the HPV vaccine.

Nigeriainfection à HPVpublié 2020African health sciencesPubMeddocument de 3 observations

51,6 %In this study, 51.6% of the 620 sexually active women aged 25–65 years in Ibadan, Nigeria preferred healthcare provider (HCP) sample collection for HPV testing.

Nigeriainfection à HPVpublié 2026BMJ openPubMeddocument de 11 observations

92,7 %Support for HPV vaccination was high at 92.7% among women and male partners in Makurdi, North-Central Nigeria.

Nigeriainfection à HPVpublié 2025Asian Pacific journal of cancer prevention : APJCPPubMeddocument de 6 observations

89 %HPV vaccination achieved 89% coverage among 14 million girls aged 9–14 in Nigeria in 2023.

Nigeriainfection à HPVobservé 2023Africa CDCdocument de 52 observations

88 %The prevalence of any HPV infection was 88% in the vulva among female sex workers in Ibadan, Nigeria.

Nigeriainfection à HPVpublié 2022PloS oneeurope_pmcdocument de 4 observations

46,8 chi_squaredA statistically significant association was observed between cervical premalignant lesions and high-risk HPV infections (χ² = 46.800, P < 0.001) among HIV-infected women.

Nigeriacervical premalignant lesions · infection à HPVpublié 2019The Pan African medical journalPubMeddocument de 5 observations

6,87 odds_ratioExposure to HPV vaccine messaging was associated with a seven times higher odds ratio of HPV vaccine uptake (aOR = 6.87, 95% CI: 6.20–7.61).

Nigeriainfection à HPVpublié 2025PloS onePubMeddocument de 4 observations

25 HPV_typesThe type-specific PCR confirmed 25 HPV types out of the 44 HPV types detected by NGS.

Nigeriainfection à HPVpublié 2023Virology journalPubMeddocument de 8 observations

3 genotypesAmong 225 participants in the TRUST/RV368 cohort in Abuja and Lagos, Nigeria, median number of anal HPV genotypes was 3.

Nigeriainfection à HPVpublié 2022Sexually transmitted diseasesPubMeddocument de 13 observations

Irregular menstruation was significantly associated with HPV infection.

Nigeriainfection à HPVpublié 2021Annals of medicinePubMeddocument de 9 observations

4,4 %Among medical, dental and allied health students in Kano, northern Nigeria, 4.4% (18) had received at least one dose of the HPV vaccine.

Nigeriainfection à HPVpublié 2022Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and GynPubMeddocument de 2 observations

79 %Majority (79%) of the respondents had a positive attitude to HPV vaccination.

Nigeriainfection à HPVpublié 2023West African journal of medicinePubMeddocument de 3 observations

41,1 %Concern about the cost of the HPV vaccine was reported as a barrier by 41.1% of female undergraduates in a university in Ekiti State, southwest Nigeria.

Nigeriainfection à HPVpublié 2023African journal of reproductive healthPubMeddocument de 5 observations

80,9 %PAR increased HPV awareness among participants from 80.9% before the intervention to 99.8% afterward.

Nigeriainfection à HPVpublié 2024BMC public healthPubMeddocument de 4 observations

92 %Majority (92%) of the respondents had poor knowledge of HPV infection and vaccination.

Nigeriainfection à HPVpublié 2023West African journal of medicinePubMeddocument de 3 observations

3,11 aORAmong participants in the TRUST/RV368 cohort, HIV infection was associated with highly similar anal HPV genotypes at 3 months (adjusted odds ratio 3.11, 95% CI 1.6–5.9).

Nigeriainfection à HPV · VIH/sidapublié 2022Sexually transmitted diseasesPubMeddocument de 13 observations

Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.